Roche’s two phase 3 studies show Hemlibra reduces bleeding in hemophilia patients
The company reported positive results from phase III Haven 3 study assessing Hemlibra prophylaxis administered every week or every two weeks in people with haemophilia A without factor
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.